CIPLA's weekly performance was disappointing, with a return of -2.13%, underperforming its peers SUNPHARMA and DIVISLAB. The stock's volatility was moderate at 20.07%, but its Sharpe Ratio of -0.42 indicates that the returns were not justified by the level of risk taken. CIPLA's performance was similar to GRASIM's, but both underperformed the peer group. The stock's risk profile was moderate, with a Max Drawdown of -3.1%.

[Volatility: 20.07%]